Non-interventional study to investigate the effectiveness of emicizumab under real-world conditions in pediatric, adolescent, adult and elderly patients with hemophilia A with and without FVIII inhibitors
Haemophilia A
Cohort A: The participants with congenital severe haemophilia A without Factor VIII (FVIII) inhibitors who are undergoing emicizumab treatment as described in the Hemlibra® (Emicizumab) summary of product characteristics (SPC), will be observed and asked to complete questionnaires every 6 months at the study centre until the end of study if emicizumab treatment is not discontinued (maximum up to 5 years). Cohort B: The participants with congenital haemophilia A (any severity) with FVIII inhibitors who are undergoing emicizumab treatment as described in the Hemlibra® (Emicizumab) SPC, will be observed and asked to complete questionnaires every 6 months at the study centre until the end of study if emicizumab treatment is not discontinued (maximum up to 5 years).
1. Participants of any age with congenital severe haemophilia A with or without FVIII inhibitors 2. Participants undergoing treatment with emicizumab according to Summary of Product Characteristics (SPC) (start of treatment with emicizumab maximum 3 months prior to study entry) 3. Must sign informed consent by the legal representative or participant or both, as required 4. Selection criteria for Cohort A include participants diagnosed with severe congenital haemophilia A (<1% FVIII activity) and no present FVIII inhibitor at the start of emicizumab treatment, patients who completed successful ITI before the start of Emicizumab treatment are eligible. 5. Selection criteria for Cohort B include participants diagnosed with congenital haemophilia A (any severity) with FVIII inhibitor activity at the start of emicizumab treatment or ongoing ITI at the start of emicizumab treatment
1. Participants having bleeding disorder other than congenital haemophilia A 2. Treatment with emicizumab outside of the SPC at study entry 3. Any contraindication for treatment with emicizumab according to current SPC 4. Current participation in an interventional study